New year, new authors are visiting the Columbus Metropolitan Library (CML). After introducing the revamped Authors at the Library series in 2025, the program is back for 2026.
Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...
Chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML) are two types of cancers that affect the blood and bone marrow. In both types, certain blood cells multiply out of control.
An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...
With recent advances, treatment for chronic myeloid leukemia (CML) can often slow or stop the progression of the disease. Today, CML may be treated similarly to a chronic long-term condition. The goal ...
LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, ...
The life expectancy of patients with recently diagnosed chronic myeloid leukemia (CML) is now approaching that of the general population, which is an important message for physicians to convey to ...
Please provide your email address to receive an email when new articles are posted on . It has been eight years since imatinib was approved as the first oral tyrosine kinase inhibitor indicated for ...
The case is believed to be just the second reported in the scientific literature. In patients with chronic myelogenous leukemia (CML), patients sometimes present with soft-tissue hematomas resulting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results